According to a
new press release, a judge in California has ordered all cases in the state against Bayer
Corporation regarding the Essure® permanent birth control device be
consolidated before a single judge in the Alameda County Superior Court.
The plaintiffs in the litigation are represented by a team of national
leaders in the fight against Essure®, including Fibich, Leebron, Copeland
& Briggs' very own Erin Copeland. Attorney Erin Copeland is a
recognized leader in Essure® litigation to help women who have been
harmed as a result of using this device.
The order by the California judge is a favorable one, helping nearly 900
women who brought forward roughly 55 actions in the state to hold Bayer
accountable. The FDA-approved medical device has been associated with
a number of alleged problems including migration, organ perforation, and
other serious health complications. In February, the FDA issued an announcement,
requiring Bayer to put a black box warning on the device, indicating that
there are risks of serious injuries associated with use of the product
that require heightened warnings. The FDA is also requiring Bayer to conduct
additional post-market studies.
All cases being heard before a single judge can help weed out inconsistent
rulings. The women can come together and pursue legal actions in a unified
manner, proving together that there are unreasonably risky side effects
associated with the use of Essure® and that the device should be removed
Attorney Erin Copeland is well-versed in matters involving this device
and one of the leaders in the Essure® litigation. She will be
speaking at the Mass Torts Made Perfect event on Thursday, October 20, 2016, detailing the Essure® litigation and
the unreasonably dangerous side effects of the device. Since 2012, Attorney
Erin Copeland’s focus has been on women’s healthcare litigation.
If you or someone you love has been harmed due to the Essure® birth
control device, we encourage you to
call us and speak to Erin Copeland of Fibich, Leebron, Copeland & Briggs today.